Tagged with Sanofi,

Pharma Bert de Jong, General Manager Benelux at Genzyme, discusses the solutions Genzyme is offering to patients suffering from rare diseases and MS in the Benelux and how these treatments add value overall to society, as well as the company’s changing role in the Sanofi organization with the addition of the oncology and…

Pharma Marc-Antoine Lucchini, the president-general manager of Sanofi France, talks about their unprecedented number of new molecules and innovations soon to be launched. He also explains the need to focus on the long-term impact of pricing and why the way Sanofi performs in France acts as a model for other affiliates across…

Sanofi The president and director general of Sanofi Morocco talks about the impact of public/private partnerships for the development of the Moroccan health sector, explains why 2013 was the African year for Sanofi and stresses the importance of visibility if Sanofi is to continue investing in large regional projects in the…

Sanofi Vaccination is one of the most important achievements of mankind. The general manager of Sanofi Pasteur Mexico shares the company’s vision behind the decision to choose Mexico as one of the company’s selected production sites worldwide, why the country provided the best conditions to develop the soon-to-be-launched dengue vaccine and…

Sanofi Sanofi’s Korean affiliate is the fifth largest recipient of clinical trial investments after the United States, France, Germany and the United Kingdom. Kay Bae, general manager, discusses the benefits of clinical testing in Korea and why ‘open innovation’ is important for progress and development.   You became general manager of…

Sanofi The director general of the Argentina, Uruguay and Paraguay region for Sanofi discusses the strength of the Argentinian healthcare system and the key, but subdued, role that multinational pharmaceutical companies play within it.     As someone who comes from abroad, how would you describe the environment here for multinationals?…

Sanofi Sanofi’s general manager for Malaysia, Singpoare and Brunei discusses the benefits of implementing of a new channel business model and proudly showcases the dengue vaccine, 20 years after the company initiated its research.   In 2010, Sanofi was undergoing a transformation to become a more diversified healthcare player. Could you tell…

vaccines Ricardo Brage serves as Vice President Spain for Sanofi Pasteur MSD. He discusses how he sought to change the subsidiary in response to pricing reforms as well as the challenges surrounding regional tenders for vaccines.   How did the joint venture of Sanofi Pasteur and MSD come to life? In…

R&D The president of Sanofi Pasteur Canada discusses the greatest challenges currently facing vaccine companies in Canada, and the added value that Canada’s R&D framework brings to a vaccine company like Sanofi Pasteur. What are the greatest challenges of the vaccine industry in Canada today? The biggest challenge is keeping ahead…

Aspen Labs Marked socio-economic differences in Mexico are playing an important role in pushing the uptake of generics, and these issues are starting to affect multinational corporations (MNCs). MNCs are being forced to open up and diversify, quite simply to have their fingers in as many pies where they can compete successfully.…

CSR The President & CEO of Sanofi Canada talks candidly about the pros and cons of the current administrative setup of the Canadian healthcare sector; Concerto, an association in Quebec that puts innovative pharma alongside government and regulators, and the local implications of the global trend of diversification in Big Pharma.…

Generics Eric Ng received his degree at National University of Singapore. In his career he has worked for such companies as AstraZeneca before moving to Sanofi-Aventis China until his rise in rank to President Director of Sanofi in Indonesia. Today he talks about the stiff competition in Indonesia in the generics…